Rise of Clinical Trials Industry in India: An Analysis
ISRN Public Health · 2013
DOI: 10.1155/2013/167059 ↗Kurz gefasst
Fachartikel in der Zeitschrift ISRN Public Health, 2013. Verfasst von Vikas Bajpai. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Clinical trials industry has seen a phenomenal increase in last ten years or so, and India has emerged as one of the foremost global destinations for clinical trials. Changed intellectual property regimen after WTO has been the prime mover of the phenomenon, and maximizing profits rather than serving any altruistic motives forms the main ideological underpinning of the rise of clinical trial industry in India. The paper examines the ideological underpinnings of the rise of clinical trials industry in the country in detail and how the ruling classes of India have tried to capitalize on this as a great economic opportunity. In the process the interests of India’s poor have been the main casualty.
Zitieren
APA
Bajpai, V. (2013). Rise of Clinical Trials Industry in India: An Analysis. ISRN Public Health. https://doi.org/10.1155/2013/167059
Vancouver
Bajpai V. Rise of Clinical Trials Industry in India: An Analysis. ISRN Public Health. 2013. doi:10.1155/2013/167059
BibTeX
@article{Bajpai2013,
author = {Bajpai, Vikas},
title = {Rise of Clinical Trials Industry in India: An Analysis},
journal = {ISRN Public Health},
year = {2013},
doi = {10.1155/2013/167059}
}
EUVIMED